PCA
RLAY icon

Pallas Capital Advisors’s Relay Therapeutics RLAY Stock Holding History

Pallas Capital Advisors’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$413K Sell
22,073
-6,500
-23% -$94.4K 0.01% 637
2026
Q1 		$284K Buy
28,573
+3,453
+14% +$30.9K 0.01% 651
2025
Q4 		$213K Buy
25,120
+20
+0.1% +$143 0.01% 801
2025
Q3 		$131K Buy
25,100
+342
+1% +$1.3K ﹤0.01% 813
2025
Q2 		$85.7K Buy
+24,758
New +$73.6K ﹤0.01% 800

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Pallas Capital Advisors's RLAY Position: Q2 2026 in Review

Pallas Capital Advisors reduced its Relay Therapeutics (RLAY) stake by 23% in Q2 2026, selling an estimated $94.4K and leaving 22,073 shares worth $413K. The position accounts for 0.01% of the portfolio, ranked #637.

Pallas Capital Advisors first reported a position in RLAY in Q2 2025 and has held it in 5 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Pallas Capital Advisors held 22,073 shares of Relay Therapeutics worth $413K as of Q2 2026.
  • Pallas Capital Advisors sold 6,500 Relay Therapeutics shares in Q2 2026, an estimated $94.4K.
  • Relay Therapeutics made up 0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #637 holding.
  • Pallas Capital Advisors first reported a position in Relay Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.